Michelle Arkin, PhD
Small Molecule Discovery Center, University of California, San Francisco
Michelle Arkin is theAssociate Director of Biology atthe Small Molecule Discovery Center and Assistant Adjunct Professor in the Department of Pharmaceutical Chemistry at UCSF. She directs the high-throughput screening facility at the SMDC and engages in grant-funded small-molecule discovery research. Dr.Arkin’s research interests are in developing innovative approaches to tackle challenging targets (such as protein-protein interfaces and allostery) and orphan/neglected diseases (including infectious and neurodegenerative diseases). Dr. Arkin receivedher PhD in chemistry at Caltech and then held aDaymon Runyon Cancer Foundation postdoctoral fellowshipat Genentech. She wasamong the firstscientistsat Sunesis Pharmaceuticals, where she helped to develop fragment-based approaches for inhibiting protein-protein interactions and biophysical tools to characterize protein/small-molecule interactions. From 2005 to 2007, she was the Associate Director of Cell Biology at Sunesis andled the translational science team for Voreloxin, an anti-cancer agent enteringphase 3 clinical trials.
Richard A. Basile
Richard Basile is Chief Executive Officer of BioPontis Alliance. BioPharmaceutical executive with 30 yrs commercial international experience within early stage and Fortune 100 Pharma/Biotech including licensing, M&A, product development and launch in anti infective, cardiovascular, immunological, dermatologic and metabolic disease segments. Mr. Basile has participated in the launch of more than 15 pharmaceutical and biological products including two top 5 global products, ciprofloxacin and nifedipine, as well as leading biotechnology and protein therapeutic products including rfVIII and IV immune globulin. Appointed VP of corporate strategy, finance, and business development of a $1.2 billion international biologics business unit with responsibility for licensing, M&A, JV, financial planning and reporting, and R&D Alliances, Mr. Basile played a leadership role on the senior executive team in the consolidation of a new global business unit at Bayer AG. (Bayer Biologicals). Prior to that appointment, Mr. Basile served in several senior marketing , sales and strategic marketing capacities’ at Bayer Pharmaceuticals, and was President and General Manager of a Bayer subsidiary, Rhein Chemie Corporation. More recently, Mr. Basile was the founding CEO of Entegrion (formerly Hemocellular Therapeutics), an early stage biotech company founded on UNC-CH invention in homeostasis, Executive VP at MylanBertek, and was the global commercial head of Diosynth Biotechnology, part of Organon Biosciences where he also served on the executive management team of Organon (now Merck & Co) responsible for biotechnology business development, with focus on oncology and immunology.
Judith A. Britz, PhD
Maryland Biotechnology Center
Dr. Judy Britz, the Executive Director of the Maryland Biotechnology Center has more than 25 years of experience in the in vitro diagnostics industry. She is a serial entrepreneur who has been the President and CEO of Cylex Inc. and the General Manager of Sienna Biotech, Inc., both Maryland-based companies which successfully introduced a series of patented diagnostic products, navigating them through the FDA in record time, manufacturing kits under GMP and marketing them to hospitals in the US, Europe, and Asia. To finance these companies, she raised over $50 million from private equity, corporate, government and angel sources. Dr. Britz previously held positions in business development and research and development at Becton Dickinson and Johnson and Johnson’s Ortho Diagnostic Division. As a research scientist at Electro-Nucleonics Inc., she was responsible for developing one of the first licensed blood screening tests for HIV.
Dr. Britz has been involved in developing and commercializing a wide variety of diagnostic technologies (manual and instrumented) with applications in infectious diseases, endocrinology, and cancer. In 2008, she founded Britz Consulting and has advised companies throughout in the United States in diagnostic as well as therapeutic areas across a broad range of applications, including stem cells. She was also a member of the Advisory Board of Stronghold Advisors, an investment banking group in Columbia, Maryland.
Dr. Britz’ academic career includes a PhD from Stanford University in Immunology and Medical Microbiology. She completed postdoctoral fellowships at Yale University and Johns Hopkins in cellular immunology. She is on the scientific advisory boards of two startup pharma companies. As an active participant in the technology community, she has held Board and advisory positions on the Greater Baltimore Committee’s Bioscience Group, The Technology Council of Maryland, Women in Bio, The Healthcare Businesswomen’s Association, The Howard County Economic Development Association, and The Horizon Foundation.
Jon L. Collins, PhD
GlaxoSmithKline Research & Development
Jon Collins received his BS degree in chemistry from the University of North Carolina at Chapel Hill and a PhD in organic chemistry with a minor in biochemistry at Indiana University at Bloomington. After completion of a postdoctoral fellowship at Harvard University in the labs of Professor Stuart Schreiber, he joined GlaxoSmithKline in 1995 and has since led drug discovery research teams that span novel target selection, hit identification and optimization in multiple target classes, lead optimization to candidate selection, and design of proof of concept clinical studies. Jon has collaborated extensively with the academic community throughout his scientific career and recently joined the Discovery Partnerships with Academia team within GlaxoSmithKline in order to establish and lead joint academic-GSK drug discovery collaborations in the US.
P. Jeffrey Conn, PhD
Vanderbilt Center for Neuroscience Drug Discovery
Dr. Conn is the Lee E. Limbird Professor of Pharmacology at Vanderbilt University and Director of the Vanderbilt Center for Neuroscience Drug Discovery. Dr. Conn received the Ph.D. degree in Pharmacology from Vanderbilt in 1986 and pursued postdoctoral studies at Yale University. Dr. Conn joined the faculty of the Department of Pharmacology at Emory University in 1988 where he where he established himself as a leader in studies of neurotransmitter receptors and their roles in regulating brain function in circuits involved in psychiatric and neurological disorders. In 2000, Dr. Conn assumed the position of Senior Director and Head of the Department of Neuroscience at Merck and Company in West Point, PA. Dr. Conn moved to Vanderbilt University in 2003 as the founding director of the Vanderbilt Program in Drug Discovery (VPDD), with a primary mission of facilitating translation of recent advances in basic science to novel therapeutics. By 2011 the VPDD had grown to approximately 100 full time scientists and raised over $80M in research funding. In addition, the VPDD advanced novel molecules from three major programs into development for clinical testing in major brain disorders with industry partners. A fourth program reached development status and is advancing internally at Vanderbilt. To mark this growth and facilitate more fluid integration of drug discovery, development, and corporate partnerships, the VPDD achieved independent center status and was named the Vanderbilt Center for Neuroscience Drug Discovery in January 2011. Dr. Conn is Editor in Chief of Molecular Pharmacology, Regional Editor (North America) of Current Neuropharmacology and serves on the editorial boards of 6 other international journals. He has served the Scientific Advisory Boards of multiple foundations and companies in the pharmaceutical and biotech industries. He currently serves as the founding director of the scientific advisory board of Karuna Pharmaceuticals and on the advisory boards of Seaside Therapeutics and the Michael J. Fox Foundation. He served as Chairman of the Neuropharmacology Division of the American Society for Pharmacology and Experimental Therapeutics (ASPET) and on multiple national and international committees. He has received numerous awards, including the NARSAD Essel Distinguished Investigator Award, the ASPET-Astellas Award in Translational Pharmacology, the Pharmacia - ASPET Award for Experimental Therapeutics, the Charles R. Park Award for Basic Research Revealing Insights into Physiology and Pathophysiology, the PhRMA Foundation Award for Excellence in Pharmacology and Toxicology. He was named as an ISI Most-Cited Scientists in Pharmacology & Toxicology and the Lee University 2008 Distinguished Alumnus of the Year. Dr. Conn’s current research is focused on development of novel treatment strategies for schizophrenia, Parkinson’s disease, and other serious brain disorders.
Natalie Dakers, President & CEO, CDRD
The Centre for Drug Research and Development
Ms. Dakers is a leading figure in the Canadian biotechnology industry and currently serves as the Chief Executive Officer of the Centre for Drug Research and Development (CDRD). CDRD was set up to address the commercialization gap between early‐stage technologies arising out of university based research and investment opportunities. Ms. Dakers brings to CDRD many valuable years of experience in the commercialization of technology, licensing and intellectual property protection. Previously, Ms. Dakers was President & CEO of Neuromed Pharmaceuticals Inc., a private biopharmaceutical company developing drugs for chronic pain, anxiety, epilepsy and cardiovascular diseases. Prior to co‐founding Neuromed, Ms. Dakers was a senior manager for life sciences technology transfer at the University Industry Liaison Office (UILO) at the University of British Columbia. In this capacity, she was involved in the creation and spin‐off of more than a dozen start‐up high‐tech and biotech companies. Currently, Ms. Dakers is a board member of the Canada Foundation for Innovation (CFI) and the International Science and Technology Partnership Canada (ISTP Canada). Previously, Ms. Dakers also served on the Boards of Genome Canada, Genome BC, and the Michael Smith Foundation for Health Research. Ms. Dakers is an Adjunct Professor in UBC’s Faculty of Pharmaceutical Sciences and a member of the Council of Canadian Academies’ Expert Panel on Business Innovation. Ms. Dakers received a Peak Award for Performance and Excellence in 2004. In 2009, Ms. Dakers was the recipient of BIOTECanada’s Gold Leaf Award for Industry Leadership.
Stephen V. Frye, PhD
The Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill
Stephen Frye is Professor and Director of the Center for Integrative Chemical Biology and Drug Discovery at UNC-Chapel Hill. His research focuses on oncology drug discovery and the chemical biology of chromatin regulation. Before joining UNC in 2007, he served as worldwide Vice President for High Throughput and Discovery Medicinal Chemistry at GlaxoSmithKline. During his 20 years at GSK, his creation and leadership of a department focused on oncology and protein kinases resulted in the discovery of several marketed drugs and he is also the inventor of Avodart, GlaxoSmithKline’s drug approved for treatment of benign prostate disease.
Robert Garland, MD
New Enterprise Associates (NEA)
Robert joined NEA in 2003 and invests in biopharmaceuticals and medical devices. He is a director of 3-V Biosciences, Cardioxyl Pharmaceuticals, Trevena, Inc., and Zyngenia. Prior to NEA, in addition to clinical practice at the University of California, San Francisco (UCSF), he was with McKinsey & Company's Pharmaceutical & Medical Products and Corporate Finance & Strategy practices. At McKinsey, Robert worked with biotech, pharmaceutical, medical device, diagnostics, and private equity clients to evaluate investments, formulate product and corporate strategies and build businesses. Robert completed his Residency in Internal Medicine and Fellowship in Infectious Diseases at UCSF and received his MBA and MPH from the University of California, Berkeley, his MD from Baylor College of Medicine, and his BS in EE/Bioengineering from Rice University.
Marcie Glicksman, PhD
The NeuroDiscovery Center's Laboratory for Drug Discovery in Neurodegeneration, Harvard
Dr. Marcie Glicksman is the Co-Director of the Laboratory for Drug Discovery in Neurodegeneration (LDDN) which is part of the Harvard NeuroDiscovery Center and assistant professor in the Neurology Department at Brigham and Women’s Hospital andHarvard Medical School. She received a bachelor’s degree from Brown University and a Ph.D. in Neuroscience from Washington University. Dr. Glicksman has extensive experience in assay development, high throughput screening, and chemical databases, as well as animal pharmacology and preclinical development. She has been in the field of drug discovery for twenty years, the most recent six years in academics and more than ten years in the pharmaceutical /biotechindustry. Before joining LDDN, she was at the start-up company, Descartes Therapeutics. Before this, she was Director of Leads Discovery at Cubist leading a group in the development of antibiotics with a structure-based drug design approach using x-ray crystallography and chemical modeling, which resulted in lead molecules suitable for testing in animal models. Before Cubist, she was in Leads Discovery at DuPont-Merck (later DuPont Pharmaceuticals) and Cell Biology at Cephalon, Inc. She led the assay development and screening programs for many cell-based and biochemical assays including a protease project and numerous G-protein coupled receptor projects. She also has led a program for Alzheimer’s and Parkinson’s disease that resulted in co-inventorship of CEP1347, a drug candidate directed at a kinase in Phase III clinical trials. She was elected in 2005 to the Board of Directors for the non-profit drug discovery organization, the Society for Biomolecular Sciences and served as its Chairman for two years. She is on the science advisory board for the Alzheimer’s disease foundation (ADDF/ISOA) and the California Institute for Regenerative Medicine (CIRM), and reviews grants for NIH and the Michael J Fox foundation. She also regularly consults and this has included filing an Investigational New Drug application with the FDA, as well as projects involving the development of new technologies.
Alex Kiselyov, PhD
CHDI Foundation, Inc.
Alex Kiselyov has spent over fifteen years in combinatorial chemistry, structure-based drug design, drug discovery, development, cGMP and preclinical services with Amgen, ImClone, ChemDiv and deCODE. He held positions of increasing responsibility at each company. Alex managed multiple preclinical programs in the areas of oncology, inflammation, cardiovascular disorders and cognition. These efforts yielded three clinical candidates. Alex’s primary expertise and interests include enabling technologies for drug discovery in both Chemistry and Biology, rational approach to development of allosteric modulators and inhibitors of protein-protein interaction in the areas of neurodegeneration and cognition, and elucidation of the origins of life on Earth.
Alex received his PhD in Synthetic Organic Chemistry from Georgia State University. He carried out post-doctoral training at the Ben May Institute for Cancer Research at the University of Chicago and Columbia University. He is a member of the Chemical Biology and Drug Design editorial board. Alex joined CHDI in 2010.
Lynn D. Kramer, MD
The Eisai Neuroscience Product Creation Unit
Lynn D. Kramer, M.D., is the President of the Eisai Neuroscience Product Creation Unit, where he oversees the full product creation cycle, including licensing activities, from discovery through regulatory approval of innovative projects in the neuroscience area. Prior to his employment at Eisai, he had positions in a number of pharma companies, large and small, during his 23 year industry career including PAR Pharmaceutical, Inc., Purdue Pharmaceuticals, Ciba Geigy, Novartis, the R.W. Johnson Pharmaceutical Research Institute, and Carter-Wallace, Incorporated. During his career he has lead teams and groups accounting for 17 NDAs and has been responsible for leading the Neuroscience Therapeutic Area Strategy Team at Ciba and Novartis, which included discovery research, clinical development, and global marketing. He is a Fellow of the American Board of Psychiatry and Neurology (1987). He has had multiple grants and has been CO-Prinicipal Investigator on a large NIH-sponsored Program Project and other projects. He has more than 90 publications (chapters, journal articles, abstracts). He received his M.D. from Hahnemann Medical College, completed his internship in Internal Medicine at the University of California at Irvine and his residency in Neurology at the University of Virginia.
Story C. Landis, PhD
Story Landis, Ph.D. has been Director of the National Institute for Neurological Disorders and Stroke (NINDS) since 2003. A native of New England, Dr. Landis received her undergraduate degree from Wellesley College (1967) and her Ph.D. from Harvard University (1973). After postdoctoral work at Harvard University, she served on the faculty of the Department of Neurobiology there. In 1985, she joined the faculty of Case Western Reserve University School of Medicine, where she created the Department of Neurosciences which, under her leadership, achieved an international reputation for excellence. Throughout her research career, Dr. Landis has made fundamental contributions to the understanding of nervous system development. She has garnered many honors, is an elected fellow of the Institute of Medicine, the Academy of Arts and Sciences, the American Association for the Advancement of Science and the American Neurological Association, and in 2002 was elected President of the Society for Neuroscience.
Dr. Landis joined the NINDS in 1995 as Scientific Director and worked to re-engineer the Institute's intramural research programs. Between 1999 and 2000, she led the movement, together with the NIMH Scientific Director, to bring a sense of unity and common purpose to 200 neuroscience laboratories from eleven different NIH Institutes. As NINDS Director, Dr. Landis oversees an annual budget of $1.5 billion that supports research by investigators in public and private institutions across the country, as well as by scientists working in its intramural program. Together with NIMH and NIA directors, she co-chairs the NIH Blueprint for Neuroscience Research, a roadmap-like effort to support trans-NIH activities in the brain sciences. In 2007, Dr. Landis was named Chair of the NIH Stem Cell Task Force.
Martin Lehr, M.A.
Osage University Partners
Martin joined Osage University Partners in 2009 and focuses on novel biopharmaceutical products, medical devices, diagnostics, and research tools. Prior to joining Osage, Martin conducted research in the areas of DNA repair at the Sloan-Kettering Institute and in thrombin activation at the Children's Hospital of Philadelphia.
He serves as a Director of Philly BioBreak, a networking group dedicated to fostering a thriving life science community in the Greater Philadelphia Area. Martin is also an advisor to the University City Science Center’s QED Program and a mentor to the University of Pennsylvania’s Life Science Management program.
Martin holds a MA in Biotechnology from Columbia University, and a BA in Economics from the University of Pennsylvania.
Sanjeev Munshi, PhD
Merck Research Laboratories
Dr. Sanjeev Munshi is a Director in the External Research and Licensing organization of the Merck Research Laboratories. Sanjeev's role is to identify partnering opportunities that fit with Merck's strategic research and development goals across all therapeutic and technology areas. Sanjeev is primarily responsible for scouting in the Southeastern and Mid-Atlantic US.
Dr. Munshi graduated from Kashmir University, India with a BS in chemistry and physics. He earned a Ph.D. in molecular biophysics (Structural biology) from Indian Institute of Science, India. Following a postdoctoral fellowship in structural virology at Purdue University and a brief stint at National Cancer Institute, Sanjeev joined the Merck Research Labs in West Point, PA. After fifteen years of basic and discovery research, Sanjeev moved into External Scientific Affairs, where he is in a scouting role.
Steven M. Paul, M.D.
Weill Cornell Medical College of Cornell University
Steven M. Paul, M.D., is the Director of the Helen and Robert Appel Alzheimer’s Disease Research Institute and Professor of Neuroscience, Psychiatry and Pharmacology at Weill Cornell Medical College. He was formerly the Executive Vice President of Science and Technology and President of the Lilly Research Laboratories (LRL) of Eli Lilly and Company. Prior to assuming his positions at Lilly and Weill Cornell Medical College, Dr. Paul served as Scientific Director of the National Institute of Mental Health (NIMH/NIH) in Bethesda, Maryland.
Dr. Paul is a member of various professional and honorary societies, which include Phi Eta Sigma; Alpha Epsilon Delta; Sigma Xi; Phi Beta Kappa; and the Alpha Omega Alpha Honorary Medical Society. He is the recipient of many honors and scientific recognitions, including: The Distinguished Service Medal of the USPHS and the Chief Scientific Officer of the Year Award. In 1997, Dr. Paul was elected to membership in the Institute of Medicine (IOM) of the National Academy of Sciences and currently serves on the IOM’s Board on Health Sciences Policy. In 2009 Dr. Paul was elected a Fellow of the American Association for the Advancement of Science (AAAS) .
Dr. Paul has authored or co-authored over 500 papers and invited book chapters and was listed as one of the most highly cited scientists in the world (top 50 in Neuroscience) (1980-2000) by the Institute for Scientific Information (I.S.I.), Philadelphia, Pennsylvania. He holds 9 patents on inventions made both at NIH and Lilly. His current work has focused on the role of apoE in the pathogenesis of Alzheimer’s disease. He is also an inventor of solanezumab, a humanized anti-Aβ monoclonal antibody currently in late-stage clinical testing by Lilly as a potential disease-modifying treatment for Alzheimer’s disease.
John Reid, PhD, MBA
John Reid is a business development leader in research alliances and licensing with a supporting scientific career in drug discovery and molecular biology. He has a record of success in delivering new drugs for clinical development by leveraging critical science and business assets in strategic alliances. He is currently responsible for early stage licensing and business development in Neuroscience at AstraZeneca Pharmaceuticals. Previous roles at AstraZeneca include, Head of the Molecular Sciences Department, responsible for exploratory research in CNS, Global Alliance Management Director, and Strategic Planning/Knowledge Management Director. Before joining Astra in 1997, he was a scientist and group leader at the Glaxo Institute for Molecular Biology in Geneva, Switzerland, and a scientist at Genentech in San Francisco. He is a graduate of the University of California, Berkeley, (Ph D), UC Davis (B Sc), U. Penn-Wharton School (CPD), and LeBow College-Drexel (MBA). He has authored 25 publications in professional journals, presented over 30 invited seminars, and was recognized in 2008 and 2010 for the “Deal of Distinction Award” from the Licensing Executive Society.
Barbara S. Slusher, PhD,
NeuroTranslational Program, Johns Hopkins Brain Science Institute
Barbara Slusher is an Associate Professor of Neurology and Psychiatry and the Director of the Brain Science Institute (BSI) NeuroTranslational Drug Discovery Program. Before joining Hopkins in September 2009, Dr. Slusher had a highly accomplished drug discovery career in the pharmaceutical industry holding positions of increasing responsibility at both large and small companies including ICI Pharmaceuticals, Zeneca (now Astra-Zeneca), Guilford Pharmaceuticals, MGI Pharma, and the Eisai Research Institute, including several years as a Senior Vice President of Research and Translational Development. She has extensive experience in drug discovery through Phase I/IIa clinical development and has participated in multiple FDA meetings and both IND and NDA regulatory filings. She has also been involved in the successful development, launch and postmarketing support of four currently marketed medicines. Dr. Slusher received her Ph.D. in Pharmacology and Molecular Sciences from the Johns Hopkins School of Medicine and a Master's degree in Administrative Science from Johns Hopkins School of Continuing Studies.
At Johns Hopkins Dr. Slusher currently leads a 20-member veteran drug discovery team of medicinal chemists, assay developers, pharmacologists, toxicologists, and pharmacokinetic/drug metabolism experts, who are engaged in identifying novel drug targets arising from JHU faculty’s research and translating them into new drug therapies for neurological disorders. She has published over 120 scientific articles and is the inventor of over 50 patents. She has been an invited speaker at many national and international scientific meetings, has served as a scientific consultant of multiple biotechnology companies. She is leading the first National Consortium for Academic Drug Discovery scientists in an effort to coordinate and enhance university-led drug discovery efforts. Most recently she has co-founded an new biotechnology company called Cerecor, to commercialize JHU drug discovery inventions.
Torben Straight Nissen, MSc, PhD
Pfizer's Centers for Therapeutic Innovation
Dr. Torben Straight Nissen is Managing Director/Head of Portfolio Management and Development Strategy. He has provided leadership to global R&D organizations in the pharmaceutical and biotech industries for more than 10 years and has advanced several products from idea to clinical proof of concept. As Managing Director/Head of Portfolio Management and Development Strategy of Pfizer's Centers for Therapeutic Innovation, he is part of Pfizer's new entrepreneurial efforts to develop highly innovative and differentiated therapeutics by integrating groundbreaking research from leading medical institutions with Pfizer's significant drug development expertise.
Prior to joining Pfizer, Dr. Straight Nissen served as Chief Operating Officer of Ascendis Pharma. In this position, he was responsible for advancing the company's portfolio of new innovative prodrugs from early preclinical proof of principle to commercialization. He joined Ascendis Pharma from a position as Senior Vice President of Moksha8 Pharmaceuticals and President of Moksha8 Biosimilars where he built and advanced its portfolio of biosimilar products. Earlier, Dr.
Straight Nissen was at Maxygen from 2000 to 2007 where he held several leadership positions, including Managing Director for Maxygen's Danish R&D operations and Senior Vice President of Global Project Management.
He began his pharmaceutical career at Novo Nordisk with a focus on protein engineering.
Dr. Straight Nissen obtained his M. Sc. in chemical engineering from the Technical University of Denmark and his Ph.D. from Carlsberg Laboratories and the Technical University of Denmark.
Robert A. Zivin, PhD
Corporate Office of Science & Technology, Johnson & Johnson
Bob is a Senior Director in the Corporate Office of Science & Technology. Bob spent 20 years in healthcare R&D, working in biotechnology, molecular diagnostics and drug discovery, before joining COSAT in 2003. This work led to several FDA approved products, with another currently in Phase 3 trials. Since joining COSAT, Bob has been working on the development of new models of collaboration, with the twin aims of facilitating academic partnering and shifting the cost-reward profile of product development. Bob is also COSAT’s East Coast “Scout”, responsible for the identification and promotion of disruptive product opportunities from academic and private innovators in this region. Prior to joining Johnson & Johnson in 1986, Bob was a Senior Research Scientist at Merck, Sharpe & Dohme Research Laboratories.
Bob received a B.S. degree in Biology from Northern Illinois University, and a Ph.D. in Microbiology from the University of Chicago. He subsequently completed a Postdoctoral Fellowship at the National Cancer Institute.